Go Symbol Lookup
Loading...

Tech vs. Pharma—What's the Best Stock Buy?

 Text Size  
Published: Monday, 29 Nov 2010 | 11:49 AM ET
By:

CNBC.com Writer

Techs or pharmeceuticals — which is the better buy for investors? Uri Landesman, president of Platinum Partners, and Philip Tasho, chief executive and chief investment officer at Tamro Capital, shared their insights.

Techs Are Still the Way to Go:

A Case of the Mondays
Investing in tech, biotech and energy, with Uri Landesman, Platinum Partners, and Philip Tasho, TAMRO Capital.

Research In Motion—“We focus on undervalued companies that have a sustainable competitive advantage and that’s what we see with RIM,” Tasho told CNBC.

“They are the leader second only to Nokia globally in the smartphone market.”

“We don’t believe Apple’s going to put them out of business,” he added. “More than 50 percent of their revenues are from overseas and that’s the fastest growing component of the market.”

Google—“Search is really the heart of the web,” he said. “And when people go online, the first thing they do is search and [Google is] able to monetize that beautifully—they facilitate 20 percent of e-commerce, second only to Amazon.com .”

In addition, Tasho also likes Range Resources .

The Case For Pharmaceuticals:

Ariad Pharmaceuticals —“They are an oncology-based stock,” Landesman said. “They can do very well and likely to get approvals soon—we think they will eventually be taken over by Merck .”

Echo Therapeutics —“It also has a bright future,” he said.

Neoprobe —“Also expecting approvals there…We think it will be the source of a bidding war between their distributors Cardinal and Covidien.”

Landesman also likes Implant Sciences .

______________________________
Scorecard—What He Said:

  • Landesman's Previous Appearance on CNBC (Nov. 1, 2010)

______________________________
More Market Views:

______________________________
CNBC Data Pages:

______________________________
Alternative Investments:

______________________________

______________________________
Disclosures:

No immediate information was available for Landesman or Tasho.

______________________________

Disclaimer

 Print
Techs or pharmeceuticals — which is the better buy for investors? Uri Landesman, president of Platinum Partners and Philip Tasho, CEO and CIO at Tamro Capital shared their insights.
  Price   Change %Change
AMZN ---
ARIA ---
ECTE ---
IMSC ---
MRK ---
NEO ---
NOK ---
BB ---
REG ---
AAPL ---
GOOG ---

   
Comments

 

More Comments

 
 

Add Comments

 

Your Comments (Up to 1100 characters):

Remaining characters

Your comments have not been posted yet.

Please review your submission to make sure you are comfortable with your entry.

Your Comments:


                
            
            
        

Featured